Curis, a biotech developing cancer drugs, has filed for a capital markets transaction—not a traditional IPO, as it already trades on Nasdaq under CRIS. The filing prices the offering at $4.02 per shar

The company leans heavily on emavusertib, an oral IRAK4/FLT3 inhibitor. Updated 2026 data showed an 86% response rate in certain CNS lymphoma patients, with the FDA and EMA signaling the study could support an accelerated approval path. A major risk: the FDA placed a partial clinical hold on its TakeAim leukemia study in March 2025. Q1 2025 financials show a $10.6M net loss, reflecting the tight cash runway typical of a clinical-stage biotech. The market backdrop is improving—the biotech IPO window has roared back in H1 2026—but investors remain highly selective. For Curis, the near-term catalyst is clear, but the regulatory overhang demands a strong stomach for risk.

The company leans heavily on emavusertib, an oral IRAK4/FLT3 inhibitor. Updated 2026 data showed an 86% response rate in certain CNS lymphoma patients, with the FDA and EMA signaling the study could support an accelerated approval path.